IBI356

Innovent Biologics (Suzhou) Co. Ltd. · Phase 2 active Small molecule

At a glance

Generic name	IBI356
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis (PHASE2)
A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IBI356 CI brief — competitive landscape report
IBI356 updates RSS · CI watch RSS
Innovent Biologics (Suzhou) Co. Ltd. portfolio CI